About
Dogma Biotech develops advanced glycosylation engineering technologies to design glycan structures that enhance therapeutic protein delivery to the central nervous system, focusing on treatment of CNS storage diseases such as Tay-Sachs.
Explore Dogma Biotech's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.